In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral selective oestrogen receptor degrader (SERD) drug camizestrant. By a margin of six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results